CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses.
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
Cytokines
Immunotherapy
Receptors, Chimeric Antigen
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
accepted:
10
12
2022
entrez:
2
1
2023
pubmed:
3
1
2023
medline:
5
1
2023
Statut:
ppublish
Résumé
To date, T cells redirected with CD19-specific chimeric antigen receptors (CAR) have gained impressive success in B-cell malignancies. However, treatment failures are common and the occurrence of severe toxicities, such as cytokine release syndrome (CRS), still limits the full exploitation of this approach. Therefore, the development of cell products with improved therapeutic indexes is highly demanded. In this project, we investigated how CD4 and CD8 populations cooperate during CD19 CAR-T cell responses and what is their specific role in CRS development. To this aim, we took advantage of immunodeficient mice reconstituted with a human immune system (HuSGM3) and engrafted with the B-cell acute lymphoblastic leukemia cell line NALM-6, a model that allows to thoroughly study efficacy and toxicity profiles of CD19 CAR-T cell products. CD4 CAR-T cells showed superior proliferation and activation potential, which translated into stronger stimulation of myeloid cells, the main triggers of adverse events. Accordingly, toxicity assessment in HuSGM3 mice identified CD4 CAR-T cells as key contributors to CRS development, revealing a safer profile when they harbor CARs embedded with 4-1BB, rather than CD28. By comparing differentially co-stimulated CD4:CD8 1:1 CAR-T cell formulations, we observed that CD4 cells shape the overall expansion kinetics of the infused product and are crucial for maintaining long-term responses. Interestingly, the combination of CD4.BBz with CD8.28z CAR-T cells resulted in the lowest toxicity, without impacting antitumor efficacy. Taken together, these data point out that the rational design of improved adoptive T-cell therapies should consider the biological features of CD4 CAR-T cells, which emerged as crucial for maintaining long-term responses but also endowed by a higher toxic potential.
Sections du résumé
BACKGROUND
To date, T cells redirected with CD19-specific chimeric antigen receptors (CAR) have gained impressive success in B-cell malignancies. However, treatment failures are common and the occurrence of severe toxicities, such as cytokine release syndrome (CRS), still limits the full exploitation of this approach. Therefore, the development of cell products with improved therapeutic indexes is highly demanded.
METHODS
In this project, we investigated how CD4 and CD8 populations cooperate during CD19 CAR-T cell responses and what is their specific role in CRS development. To this aim, we took advantage of immunodeficient mice reconstituted with a human immune system (HuSGM3) and engrafted with the B-cell acute lymphoblastic leukemia cell line NALM-6, a model that allows to thoroughly study efficacy and toxicity profiles of CD19 CAR-T cell products.
RESULTS
CD4 CAR-T cells showed superior proliferation and activation potential, which translated into stronger stimulation of myeloid cells, the main triggers of adverse events. Accordingly, toxicity assessment in HuSGM3 mice identified CD4 CAR-T cells as key contributors to CRS development, revealing a safer profile when they harbor CARs embedded with 4-1BB, rather than CD28. By comparing differentially co-stimulated CD4:CD8 1:1 CAR-T cell formulations, we observed that CD4 cells shape the overall expansion kinetics of the infused product and are crucial for maintaining long-term responses. Interestingly, the combination of CD4.BBz with CD8.28z CAR-T cells resulted in the lowest toxicity, without impacting antitumor efficacy.
CONCLUSIONS
Taken together, these data point out that the rational design of improved adoptive T-cell therapies should consider the biological features of CD4 CAR-T cells, which emerged as crucial for maintaining long-term responses but also endowed by a higher toxic potential.
Identifiants
pubmed: 36593069
pii: jitc-2022-005878
doi: 10.1136/jitc-2022-005878
pmc: PMC9809278
pii:
doi:
Substances chimiques
Antigens, CD19
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: CBon received research support from Intellia Therapeutics. ABo is currently an employee of AstraZeneca. His contribution to this work relates to the period 2016–2017 when he was an employee of Vita-Salute San Raffaele University. The other authors declare no competing interests.
Références
Blood Adv. 2016 Dec 27;1(3):265-269
pubmed: 29296941
Am J Hematol. 2020 Nov;95(11):1324-1333
pubmed: 32744738
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
Cell. 2020 Jun 25;181(7):1612-1625.e13
pubmed: 32497499
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Cancers (Basel). 2016 Mar 15;8(3):
pubmed: 26999211
Nat Med. 2020 Dec;26(12):1878-1887
pubmed: 33020644
Lancet. 2021 Jul 24;398(10297):314-324
pubmed: 34175021
Clin Pharmacol Ther. 2022 Jul;112(1):81-89
pubmed: 35156195
Sci Immunol. 2021 Mar 26;6(57):
pubmed: 33771887
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
J Immunol. 2016 Dec 15;197(12):4674-4685
pubmed: 27849169
Nature. 2022 Feb;602(7897):503-509
pubmed: 35110735
J Clin Invest. 2022 Jun 15;132(12):
pubmed: 35503659
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
J Clin Oncol. 2017 Sep 10;35(26):3010-3020
pubmed: 28715249
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Sci Transl Med. 2011 Aug 10;3(95):95ra73
pubmed: 21832238
Mol Ther. 2020 Aug 5;28(8):1783-1794
pubmed: 32485137
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Breast Cancer Res. 2018 Feb 26;20(1):15
pubmed: 29482642
Blood. 2011 Nov 3;118(18):4817-28
pubmed: 21849486
JCI Insight. 2018 May 17;3(10):
pubmed: 29769444
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Nat Med. 2017 Jan 6;23(1):18-27
pubmed: 28060797
Sci Transl Med. 2017 Nov 22;9(417):
pubmed: 29167392
Nature. 2022 Mar;603(7900):328-334
pubmed: 35197632
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Mol Ther. 2018 Aug 1;26(8):1896-1905
pubmed: 29910179
Am J Hematol. 2019 May;94(S1):S42-S49
pubmed: 30784102
Sci Transl Med. 2014 Nov 5;6(261):261ra151
pubmed: 25378643
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Nat Rev Immunol. 2022 Feb;22(2):85-96
pubmed: 34002066
Sci Signal. 2018 Aug 21;11(544):
pubmed: 30131370
Nat Med. 2019 Sep;25(9):1341-1355
pubmed: 31501612
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Nat Med. 2011 Sep 18;17(10):1290-7
pubmed: 21926977
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
Nat Rev Clin Oncol. 2022 May;19(5):342-355
pubmed: 35318469
Methods Mol Biol. 2016;1393:105-11
pubmed: 27033220
Nature. 2018 Dec;564(7735):268-272
pubmed: 30479382
Cancer Discov. 2020 May;10(5):702-723
pubmed: 32193224
J Immunother. 2009 Apr;32(3):207-18
pubmed: 19242379
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
JCI Insight. 2018 Jan 11;3(1):
pubmed: 29321369
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Blood Rev. 2019 Mar;34:45-55
pubmed: 30528964
Sci Transl Med. 2022 Jan 19;14(628):eabg3072
pubmed: 35044789
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
J Immunother Cancer. 2022 May;10(5):
pubmed: 35577500